Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-517-7330
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$840,000.00
Profitability
Miscellaneous
Employees12
OptionableNot Optionable
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions
What is Cyclacel Pharmaceuticals' stock symbol?
Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."
When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?
Shares of Cyclacel Pharmaceuticals reverse split on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.
How were Cyclacel Pharmaceuticals' earnings last quarter?
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) announced its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.04. View Cyclacel Pharmaceuticals' Earnings History.
When is Cyclacel Pharmaceuticals' next earnings date?
What price target have analysts set for CYCC?
3 equities research analysts have issued 12 month price targets for Cyclacel Pharmaceuticals' shares. Their forecasts range from $6.25 to $8.00. On average, they anticipate Cyclacel Pharmaceuticals' share price to reach $7.0833 in the next twelve months. This suggests a possible upside of 796.6% from the stock's current price. View Analyst Price Targets for Cyclacel Pharmaceuticals.
What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals.
Has Cyclacel Pharmaceuticals been receiving favorable news coverage?
News coverage about CYCC stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cyclacel Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of Cyclacel Pharmaceuticals' key competitors?
Some companies that are related to Cyclacel Pharmaceuticals include OncoSec Medical (ONCS), MOTIF BIO PLC/S (MTFB), Moleculin Biotech (MBRX), Relmada Therapeutics (RLMD), Diamedica Therapeuti (DMAC), Aptevo Therapeutics (APVO), Agile Therapeutics (AGRX), Lipocine (LPCN), Oncolytics Biotech (ONCY), ContraFect (CFRX), ProPhase Labs (PRPH), Oncomed Pharmaceuticals (OMED), Neurotrope (NTRP), Heat Biologics (HTBX) and Addex Therapeutics (ADDXF).
Who are Cyclacel Pharmaceuticals' key executives?
Cyclacel Pharmaceuticals' management team includes the folowing people:
- Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)
- Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)
- Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)
- Ms. Gill Christie, Director of HR (Age 62)
- Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75)
How do I buy shares of Cyclacel Pharmaceuticals?
Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cyclacel Pharmaceuticals' stock price today?
One share of CYCC stock can currently be purchased for approximately $0.79.
How big of a company is Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals has a market capitalization of $9.87 million and generates $840,000.00 in revenue each year. Cyclacel Pharmaceuticals employs 12 workers across the globe.
What is Cyclacel Pharmaceuticals' official website?
How can I contact Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]
MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
